Quantum BioPharma announced a public whistleblower policy with a potential cash reward of up to $7M to any individual or entity who can provide definitive and verifiable proof that they were asked, instructed, hired, or otherwise induced to manipulate the Company’s stock. The following individuals or entities are not eligible to receive rewards: current directors, officers, or employees of the Company; members of law enforcement, regulatory agencies, or government officials acting in an official capacity; individuals who obtained information unlawfully or in violation of legal or professional duties; and individuals who knowingly submit false, misleading, or fabricated information. The Company will not use the information until the information provider gives consent to the Company to use the information. The cash reward of up to $7M will be paid if that information tangibly and significantly contributes evidence which leads to a final, non-appealable judgment in favour of the Company, or a binding settlement. This information includes, but is not limited to, evidence of tactics used such as: illegal “spoofing” trades or, at another’s behest; the deliberate spreading of false or misleading information about the Company across the internet; selling shares that are not timely delivered; andlending shares you do not have. The whistleblower reward will only be paid out from the net proceeds of the Company’s ongoing lawsuit, once resolved. This reward can be shared between multiple parties providing different information.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma Sets Record Date for Special Dividend Linked to Litigation Proceeds
- Quantum BioPharma announces record date for special dividend distribution
- Quantum BioPharma Advances Lucid-MS with Key Study Reports
- Quantum BioPharma receives final reports for two studies of Lucid-21-302
- Quantum BioPharma Strengthens MS Program with New Clinical Advisor